Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnevist Dose Comparison for Delayed Enhancement in MI
NCT00310544Phase 2Completed
- Sponsor
- Bayer
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial of gadopentetate dimeglumine in myocardial infarction (MI) (2 arms), sponsored by Bayer. Primary endpoint: Quantitative measurement of the total area of delayed enhancement. Started Mar 2006; status: completed.
02
Drugs
gadopentetate dimeglumine
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT00310544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00310544.